The use of intravenous iron in patients with cancer‐related anaemia
- 22 April 2008
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 141 (6) , 751-756
Abstract
Summary: Intravenous iron has become the standard of care in patients with renal failure receiving treatment with erythropoiesis stimulating agents (ESAs) to treat true and functional iron deficiency and to prevent its development in haemodialysis patients. In cancer‐related anaemia, several recently published, randomised studies suggested that intravenous iron improved haemoglobin response rates in ESA‐treated patients compared to those treated with oral iron or placebo. The data supporting the efficacy of intravenous iron instead of oral iron in this setting are increasingly persuasive but larger randomised trials are needed before definitive recommendations are made.Keywords
This publication has 36 references indexed in Scilit:
- Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4Blood, 2007
- Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapyGynecologic Oncology, 2007
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEuropean Journal of Cancer, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Intravenous Iron Therapy in End‐Stage Renal DiseaseSeminars in Dialysis, 2006
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal of Cancer, 2004
- Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized TrialJournal of Clinical Oncology, 2004
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 2003
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986